A Western Europe-based fund is interested in advanced therapeutics. The firm invests both publicly and privately throughout the US, and Europe. For private deals, the firm makes equity deals in early-stage biotech therapeutic companies. The firm typically looks to make 8-10 deals in the private sector through each yearly cycle and typically allocates between $1M – $5M in each deal. The firm typically follows on these investments, preferring not to lead.  The firm typically invests in seed and Series A rounds.

The firm is currently seeking biotech therapeutics that are considered advanced therapeutics. Examples of some therapies that the firm considers as advanced therapies are cell therapies and gene therapies. Currently, the firm is interested in immuno-oncology therapeutics, but is not interested in checkpoint inhibitors. For these therapeutics companies, they prefer that the asset is currently pre-clinical, in Phase I, or ready for phase II. The firm is agnostic in terms of specific indications.

The firm prefers investing in companies located in the European Union, but typically finds that a good amount of their deals are based in the United States. The firm is open to other geographies, but has yet to see a deal that is particularly interesting to them from other areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new venture capital firm located in the USA focuses on the life science industrials and invests in companies that develop tools, technologies, and services for discovery, development, and manufacturing of biologics and related therapies. The firm is focused on early stage venture and growth equity investments. Typical equity investments range from $500k-$5 million. The firm expects to make 4-8 investments in the coming 18 months and is open to either leading or co-leading in a financing round.

Within life sciences, the firm is specifically focused on life science industrials: the tools, technologies, and services that enable the discovery, development, and manufacturing of life-saving therapies. The firm do not invest in therapeutics or medical devices. The firm considers Seed to Series B stage opportunities.

The firm partners with entrepreneurs and their teams to overcome inflection points in growth. The firm takes a hands-on approach to working with its portfolio companies through focused operational and commercial guidance and an engaged approach to supporting entrepreneurial ventures.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm invests across multiple funds, with each fund focused on a sector of strategic interest to the parent organization. The firm typically leads or co-leads rounds as a member of a syndicate of investors. The firm is actively seeking new investment opportunities across all funds.

The firm’s healthcare fund is looking for early stage companies working primarily within therapeutics. The firm seeks to invest in areas of strategic interest to its parent company including Immunology (Autoimmune), Oncology, Immuno-oncology, and Fertility. The firm generally looks for companies with novel first-in-class preclinical stage assets as well as novel platform technologies.

The firm is looking for privately held companies with experienced management teams able to take innovative solutions into commercially viable products. The firm looks to take an active role following investing taking a board seat, and is able to invest globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage life science development group currently backs more than 12 companies and the firm’s total investment across all technologies exceeds $100 million. The firm has a dual development strategy. The firm partners with academic inventors to found, manage, and develop companies to a point of exit or strategic partnering. When founding companies, the firm leverages non-dilutive grant funding where available alongside their investment group. The firm can also support early clinical-stage companies looking for financial and management support to perform clinical proof of concept studies; specifically a combination of investor funding and management support to round out the capabilities of the existing team. The firm and its affiliated investor groups have the ability to lead investment rounds of up to $20 million while also providing any required management support through its experienced team, including in preclinical, clinical and business development.

The firm invests across the biosciences space including Therapeutics, Diagnostics, and Medical Devices although the primary focus is on Therapeutics. The group is opportunistic in terms of subsectors and indications. Historically, the group has been active with companies developing novel therapeutics including drugs for defending against inhaled pathogenic threats, treatment of asthma, cancer, autoimmune diseases, and hearing loss, a biomedical assay platform technology, molecular diagnostics, antioxidant nanoparticles, robotic and imaging technologies, and cardiovascular devices.

The firm is interested in connecting with companies looking to generate clinical proof-of-concept data and that require funding as well as management support to complement the existing team. We are especially interested in companies that may have an interest in relocating to Houston.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm based in the USA looks to make Series A equity investments ranging from $250,000 to $1.5 million in the initial round with up to $3 million reserved for follow on financing. Only on a case-by-case basis will the firm look to make seed investments. The firm focuses on companies in the United States and may also consider exceptional opportunities in Canada.

The firm is interested in investing in companies in the Medical Device, Diagnostics and to a much lesser extent Therapeutics spaces. The firm has a much stronger focus on devices with approximately 75% of the firm’s investments to date falling into those sectors. For Medical Devices the firm generally looks for companies that have either an early prototype or proof-of-concept data to support them. The firm is also currently interested in companies working with diagnostic devices and is not looking for companies in Orthopedics and Pain. For therapeutics companies the firm generally makes investment in pre-clinical assets and will evaluate opportunities on a case-by-case basis with priority given to less capital intensive opportunities.

The firm seeks privately held companies and maintains very positive and productive working relationships with its portfolio companies, providing as much assistance as needed.  The firm is much more open to taking significant scientific and technical risk as opposed to sales and marketing challenges.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital investment firm established in China with an additional office in the USA is investing from a fund with a focus on high-tech enterprises in China and western countries. The company seeks to invest in innovative enterprises in sectors including: biomedicine, medical devices, healthcare and bio-tech. Typical equity investments range from $1-6 million in Angel, Series A and B rounds. The firm is looking for opportunities in China, the US and Canada.

Within healthcare, the firm considers biomedicine, medical devices, and digital health. The firm is most interested in personalized medicine products with an angle to the China market. Within digital health, the firm prefers home-care, consumer, or physician-patient interface products. The firm considers products from Angel Round to Series B.

The firm is looking for competent management teams. The firm may request distribution rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm founded in 2018 invests in early-stage biotech and pharma companies. The firm invests in seed to Series A investment while it can also provide later funding (follow-up investment). The firm also seeks to In-licensing and NewCo spinout for later-stage research projects. The firm also has 30,000+ square feet of chemistry/biology incubator space in the USA. The firm also shares the same investment philosophy with its parent company, a global innovation incubator and investment group supported by Chinese partners.

The firm mainly looks at the biopharmaceutical industry. The firm prefers to work closely with scientific innovators to advance discoveries rapidly through key value-inflection points.

The firm does not have specific company requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.